Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

Inclusion Criteria:

• Histologically confirmed malignancy for which there is no standard or effective curative or palliative therapy

  • Solid tumors and lymphoma allowed
  • Metastatic or unresectable disease

• Measurable or evaluable nonmeasurable disease

  • Evaluable nonmeasurable disease includes ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonis, inflammatory breast disease, abdominal masses not followed by CT scan or MRI, or cystic lesions
  • Disease characterized by elevated serum tumor marker alone is allowed
• No known brain metastases
• Performance status - ECOG 0-2
• Performance status - Karnofsky 60-100%
• More than 3 months
• Absolute neutrophil count at least 1,500/mm^3
• Platelet count at least 100,000/mm^3
• Bilirubin no greater than 1.5 mg/dL
• AST and ALT no greater than 2.5 times upper limit of normal
• No history of portal hypertension
• No history of cirrhosis or hepatitis
• No radiographic evidence of cirrhosis and/or varices
• Creatinine normal
• Creatinine clearance at least 60 mL/min
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No prior allergic reaction attributed to compounds of similar chemical or biological composition to oblimersen or other study agents
• No other concurrent uncontrolled illness that would preclude study participation
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study compliance
• No concurrent prophylactic colony-stimulating factors such as filgrastim (G-CSF) or sargramostim (GM-CSF)

• Concurrent interventional growth factors allowed

  • No growth factor administration within 24 hours before study chemotherapy
• Concurrent epoetin alfa allowed
• No more than 3 prior chemotherapy regimens
• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• More than 2 weeks since prior hormonal therapy
• Concurrent megestrol for anorexia/cachexia allowed
• No prior pelvic or whole abdominal radiotherapy
• More than 4 weeks since prior radiotherapy
• More than 4 weeks since prior major surgery
• Recovered from prior therapy
• More than 4 weeks since prior investigational therapy
• No prior oblimersen
• No other concurrent investigational agents
• No other concurrent anticancer therapy
• No concurrent combination antiretroviral therapy for HIV-positive patients